Goflikicept

戈夫利奇西普

Report date: 2024/05/16 16:36:34

Base Information

Drug NameGoflikicept
Drug Alias NameRPH-104
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionSignal transduction pathway inhibitorsInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Schnitzler SyndromeFamilial Mediterranean Fever +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryArmeniaUnited StatesTurkey +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTrpharm
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm Overseas IncTrpharmR-Pharm Jsc +[4] 
Inactive CompaniesN/A
Active IndicationsFamilial Mediterranean FeverPericarditisST Elevation Myocardial Infarction +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Schnitzler SyndromeGout +[4] 

Other Information

ATC CodeN/A
Related LinksN/A